Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov7410.25208/0042-4609-2014-90-5-112-116DRUG TREATMENT IN DERMATOVENEROLOGYФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИTopical methylprednisolone aceponate and dexpanthenol in the treatment of patients with atopic dermatitisМетилпреднизолона ацепонат и декспантенол в топической терапии больных атопическим дерматитомChikinV. V.ЧикинВ. В.
Russian Federation
State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian FederationФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России2410201490511211624082017Copyright ©; 2014, Chikin V.V.Copyright ©; 2014, Чикин В.В.2014Chikin V.V.Чикин В.В.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/74

The goals of the topical treatment of patients suffering from atopic dermatitis are suppression of the inflammatory reaction in the skin, elimination of itching, and recovery of the damaged protective lipid barrier of the epidermis. In this connection, topical glucocorticosteroids and skin moisturizers are used in the therapy of patients suffering from atopic dermatitis. Methylprednisolone aceponate (MPA, Advantan) being a topical glucocorticosteroid is characterized by high efficacy and safety. MPA is marked by the fast development of the therapeutic effect. This drug can be used for children older than 4 months and can be applied once a day. The availability of four dosage forms of MPA (emulsion, cream, ointment and fatty ointment) enables physicians to select a therapy with the use of this drug depending on the stage and localization of the skin lesion. Dexpanthenol (Bepanthen) being a tissue repair stimulator moisturizes the skin, protects the skin against an irritant effect, and restores the protective lipid barrier of the epidermis. The use of a combination of MPA being a topical glucocorticosteroid and dexpanthenol being a tissue repair stimulator can enhance the efficacy of the treatment of patients suffering from atopic dermatitis.

Целями топической терапии больных атопическим дерматитом являются подавление воспалительной реакции в коже, устранение зуда, восстановление разрушенного защитного липидного барьера эпидермиса. В связи с этим в терапии больных атопическим дерматитом используются топические глюкокортикостероиды и средства, увлажняющие кожу. Высокой эффективностью и безопасностью характеризуется топический глюкокортикостероид метилпреднизолна ацепонат (МПА, Адвантан). Для МПА характерно быстрое развитие терапевтического эффекта. Препарат может применяться у детей, начиная с возраста 4 месяца, его можно использовать 1 раз в сутки. Наличие у МПА 4 лекарственных форм (эмульсия, крем, мазь и жирная мазь) позволяет выбирать терапию этим препаратом с учетом стадии и локализации поражения кожи. Стимулятор репарации тканей декспантенол (Бепантен) увлажняет кожу, защищает ее от воздействия раздражителей, восстанавливает защитный липидный барьер эпидермиса. Использование комбинации топического глюкокортикостероида МПА и стимулятора репарации тканей декспантенола может повысить эффективность терапии больных атопическим дерматитом.

атопический дерматиттопическая терапияметилпреднизолона ацепонатдекспантенолatopic dermatitistopical treatmentmethylprednisolone aceponatedexpanthenolSchmid-Grendelmeier P., Simon D., Simon P. et al. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56: 841-849.Wüthrich B., Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the "IgE-associated ("extrinsic") and the nonallergic ("intrinsic”) AEDS. J Investig Allergol Clin Immunol 2003; 13: 1-5.Wüthrich B., Cozzio A., Roll A. et al. Atopic eczema: genetics or environment? Ann Agric Environ Med 2007; 14: 195-201.Metz M., Wahn U., Gieler U. et al. Chronic pruritus associated with dermatologic disease in infancy and childhood: Update from an interdisciplinary group of dermatologists and pediatricians. Pediatr Allergy Immunol 2013: 24: 527-539.Slattery M.A., Essex M.J., Paletz E.M. et al. Depression, anxiety and dermatological quality of life in adoloscents with atopic dermatitis. J Allergy Clin Immunol 2011; 128 (3): 668-671.Dalgard F., Lien L., Dalen I. Itch in the community: associations with psychosocial factors among adults. J Eur Acad Dermatol Venerol 2007; 21 (9): 215-219.Weisshaar E., Diepgen T.L., Bruckner T. et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behavior and SCORAD severity in 823 children. Acta Derm Venereol 2008; 88 (3): 234-239.Eichenfield L.F., Tom W.L., Berger T.G. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71 (91): 116-132.Adaskevich V.P., Baltabaev M.K.. Korsunskaya I.M. i soavt. Konsensus dermatologov stran SNG po dermatitam i ekzeme. Consilium Medicum. Dermatologiya. 2014: Ekstravypusk, 18 S. [Адаскевич В.П., Балтабаев М.К., Корсунская И.М. и соавт. Консенсус дерматологов стран СНГ по дерматитам и экземе. Consilium Medicum. Дерматология. 2014: Экстравыпуск, 18 с.]Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatol Treatm 1992; 3 (Suppl. 2): 13-15.Garcia Ponte L., Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. 2012; 26 (Suppl.6): 9-13.Luger T.A. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 2011; 25: 251-258.Bieber T., Vick K., Fölster-Holst R. et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007; 62 (2): 184-189.Günther C., Kecskes A., Staks T., Täuber U. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan® lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol 1998; 11: 35-42.Ruzicka T. Methylprednisolone aceponate* in eczema and other inflammatory skin disorders - a clinical update. Int J Clin Pract 2006; 60 (1): 85-92.Hoffmann K., Auer T., Stücker M. et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol 1998; 10: 137-142.Akdis C.A., Akdis M., Bieber T. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology / American Academy of Allergy, Asthma and Immunology / PRACTALL Consensus Report. Allergy 2006; 61: 969-987.Szczepanowska J., Reich A., Szepietowski J.C. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614-618.Goujon C., Alleaume B., De Bony R., Girard P. Randomised single-blind pilot comparison study of the efficacy and tolerability of Bepanthen ointment in subjects with bilateral dryness of the hands. Realitees Therapeutiques en Dermato-Venerologie 1997; 66: 47-33.Gehring W., Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of human in vivo study. Arzneimittelforsch 2000; 50: 659-663.Camargo F.B. Jr., Gaspar L.R., Maia Campos P.M. Skin moisturizing effects of panthenol-based formulations. J Cosmet Sci 2011; 62: 361-370.Proksch E., Nissen H.P. Dexpanthenol enhances skin barrier repair and redusec inflammation after sodiom lauryl sulphate-induced irritation. J Dermatolog Treat 2002; 13: 173-178.Biro K., Thaci I.D., Ochsendorf F.R. et al. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis 2003; 49: 80-84.Ebner F., Heller A., Rippke F., Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 2002; 3: 427-433.Wiederholt T., Heise R., Skazik C. et al. Calcium pantothenate modulates gene expression in proliferating human dermal fibroblast. Exp Dermatol 2009; 18: 969-978.Girard P., Beraud A., Goujon C. et al. Effect of Bepanthen ointment on the graft-donor site wound-healing model: double-blind biometrological and clinical study, with assessment by the patient, versus the vehicle. Nouv Dermatol 1998; 17: 559-570.Heise R., Scazik C., Marquardt Y. et al. Dexpanthenol modulates gene expression in skin wound healing in vivo. Skin Pharmacol Physiol 2012; 25: 241-248.Bahmer F., Pigatto P., Wehmeyer A. Adjuvante Hautpflege mit den dexpanthenolhaltigen Formen von pH5-Eucerin. Dtsch Derm 1997; 45 (4): 366-373.Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol 2012; 11: 366-374.